Journal of aerosol medicine and pulmonary drug delivery
-
J Aerosol Med Pulm Drug Deliv · Feb 2015
Comparative StudyMeasurements of droplet size distribution and analysis of nasal spray atomization from different actuation pressure.
To evaluate the deposition efficiency of spray droplets in a nasal cavity produced from a spray device, it is important to determine droplet size distribution, velocity, and its dispersion during atomization. Due to the limiting geometric dimensions of the nasal cavity airway, the spray plume cannot develop to its full size inside the nasal vestibule to penetrate the nasal valve region for effective drug deposition. ⋯ The experimental technique presented is able to capture a more complete representation of the droplet size distribution and the atomization process during an actuation. The measured droplet size distribution produced can be related to the empirically defined deposition efficiency curve of the nasal cavity, allowing a prediction of the likely deposition.
-
J Aerosol Med Pulm Drug Deliv · Feb 2015
ReviewNebulized medications for the treatment of dyspnea: a literature review.
Dyspnea significantly impacts quality of life and is one of the most common symptoms in advanced illness. Systemically-administered opioids and benzodiazepines have been the most studied and utilized pharmacologic treatments for refractory dyspnea. Less attention has been given to the use of these medications and others when nebulized. This article presents a review of the literature on the use of nebulized medications for the treatment of dyspnea related to cancer, chronic obstructive pulmonary disease, cystic fibrosis, interstitial lung disease, or experimentally-induced dyspnea. ⋯ More research is needed to assess the characteristics of specific diseases and the combination of different nebulizers and medications that may yield the greatest benefit, and to assess the safety and efficacy of the chronic use of nebulized opioids and furosemide. Until larger, longer-term studies are completed, the use of nebulized medications to treat dyspnea should be assessed on a case-by-case basis and may be considered if the hoped-for benefits outweigh potential harm.